Multi-Refractory MM: After Immunotherapy, What?October 25, 2024Multiple MyelomaGene TherapyCellular Therapy
Lymphoma Debate: CAR T Not a Clear WinnerOctober 25, 2024Non-Hodgkin LymphomaGene TherapyCellular Therapy
Expert Updates Therapy for Waldenström MacroglobulinemiaOctober 25, 2024Non-Hodgkin LymphomaGene Therapy
Time Warp: Fax Machines Still Common in Oncology Practice. Why?July 3, 2024DLBCLGene TherapyMixed TopicsPediatricsAggressive LymphomasALLAML
Doctors Endorsing Products on X May Not Disclose Company TiesJune 19, 2024DLBCLGene TherapyMixed TopicsBusiness of MedicineAggressive LymphomasALLAML
Survey Spotlights Identification of Dermatologic Adverse Events From Cancer TherapiesMay 13, 2024Mixed TopicsDLBCLPatient & Survivor CareCLLCMLAggressive LymphomasALL
Most Targeted Cancer Drugs Lack Substantial Clinical BenefitApril 17, 2024DLBCLGene TherapyPatient & Survivor CarePediatricsMixed TopicsBusiness of MedicineALL
Less Than 50% of Accelerated Approvals Show Clinical BenefitApril 9, 2024DLBCLMixed TopicsPatient & Survivor CareAggressive LymphomasALLAMLB Cell Lymphoma
Unleashing Our Immune Response to Quash CancerFebruary 21, 2024Gene TherapyMixed TopicsPatient & Survivor CarePediatricsAggressive LymphomasALLAML
Sickle Cell CRISPR Gene Therapy May Offer Patients ‘Functional Cure’December 19, 2023Bleeding DisordersGene Therapy
This test may guide AML therapy for Black pediatric patientsDecember 11, 2023AMLGene TherapyDiversity in Medicine
FDA approves first 2 gene-editing therapies for sickle cellDecember 8, 2023Gene TherapyBleeding Disorders
